Karyopharm Therapeutics (KPTI) Debt Ratio (2024 - 2025)
Karyopharm Therapeutics (KPTI) reported Debt Ratio of 1.07 for Q4 2025, up 85.64% on a YoY basis from 0.58 in Q4 2024, and up 6.63% quarter-over-quarter from 1.0 in Q3 2025.
Karyopharm Therapeutics (KPTI) Debt Ratio (2024 - 2025) Analysis & Trends
Karyopharm Therapeutics has reported Debt Ratio for 2 years, with the latest figure at 1.07 in Q4 2025.
- For the quarter ending Q4 2025, Debt Ratio rose 85.64% year-over-year to 1.07; the trailing twelve-month figure through Dec 2025 stood at 1.07 (up 85.64% YoY), and the FY2025 full-year result was 1.07, up 85.64% from the prior year.
- Debt Ratio for Q4 2025 stood at 1.07, up from 1.0 in the prior quarter.
- The five-year high for Debt Ratio was 1.07 in Q4 2025, with the low at 0.44 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 0.18 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn | 1.07 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.07 |
| Sep 30, 2025 | 1.00 |
| Jun 30, 2025 | 0.91 |
| Mar 31, 2025 | 0.75 |
| Dec 31, 2024 | 0.58 |
| Sep 30, 2024 | 0.50 |
| Jun 30, 2024 | 0.44 |